5 unknown. 4 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Unknown 4 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Cyclophosphamide,Fludarabine: new trials by email Literature Review of Cyclophosphamide,Fludarabine trials Research Report on Cyclophosphamide,Fludarabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide,Fludarabine - CD19+ and CD 22+ B-ALL | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 100 | 2021-08-15 | 2022-02-07 |
| A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Non-hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 200 | 2020-10-22 | 2020-12-14 |
| Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Plasma Cell Tumors | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 60 | 2020-10-22 | 2020-12-11 |
| A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Hodgkin's Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-10-22 | 2020-12-29 |
| Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis - Leukemia, Lymphoma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 30 | 2020-06-23 | 2020-10-30 |
Hodgkin Disease (1) · Leukemia (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Plasmacytoma (1)
Hebei Senlang Biotechnology Inc., Ltd. (5)
China (5)
Baoen Shan, PhD & MD (3) · Lihong Liu, PhD & MD (3) · Lian Jiang, MD (1) · Peihua Lu, PhD&MD (1)